As anticipated, and validating our screen design, inhibitors of CREBBP and its paralogue EP300 (the CREBBP/EP300-specific bromodomain inhibitor Inobrodib and the CREBBP/EP300 acetylase inhibitor A485) exhibited synthetic lethality, consistent with previous reports in B-cell lymphoma (Fig. 1b, c and Supplementary Data Table 1 and Fig. 1c)18. The gene discussed is CREBBP; the disease is B-cell non-Hodgkin lymphoma.